Previous 10 | Next 10 |
2024-01-10 08:01:12 ET Summary Data readout from phase 2 GALAXIES Lung-201 study, using belrestotug in combination with dostarlimab to treat patients with 1st-line advanced/metastatic NSCLC, expected 2024. The global non-small cell lung cancer market is expected to reach $36.9 bil...
2024-01-09 07:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-01-08 14:03:59 ET More on iTeos Therapeutics iTeos Therapeutics: Trying Hard Where The Big Guys Might Still Fail Seeking Alpha’s Quant Rating on iTeos Therapeutics Historical earnings data for iTeos Therapeutics Financial information for iTeos The...
- TIGIT program clinical data readouts anticipated in 2024, including two Phase 2 trials assessing belrestotug + dostarlimab in 1L NSCLC and 1L HNSCC - Adenosine portfolio clinical data readouts anticipated in second half of 2024, including inupadenant’s Phase 2 A2A-005 and EOS-984...
WATERTOWN, Mass. and GOSSELIES, Belgium, Jan. 03, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that Michel Det...
2023-12-15 04:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
WATERTOWN, Mass. and GOSSELIES, Belgium, Nov. 21, 2023 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immune-oncology therapeutics for patients, today announced that management...
iTeos Therapeutics Inc. (ITOS) is expected to report $-1.2 for Q3 2023
2023-11-07 08:26:49 ET More on iTeos Therapeutics iTeos Therapeutics: Trying Hard Where The Big Guys Might Still Fail iTeos Therapeutics And The TIGIT Ticket To Cancer's Downfall Seeking Alpha’s Quant Rating on iTeos Therapeutics Historical earnings da...
- Initiation of GALAXIES H&N-202, a Phase 2 platform study assessing TIGIT:PD-1 doublet and other novel IO combinations, including a CD96 triplet in HNSCC - Completed enrollment of monotherapy dose escalation arm in TIG-007 Phase 2 trial in multiple myeloma - Completed enrollment ...
News, Short Squeeze, Breakout and More Instantly...
iTeos Therapeutics Inc. Company Name:
ITOS Stock Symbol:
NASDAQ Market:
Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...
WATERTOWN, Mass. and GOSSELIES, Belgium, April 07, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced a poster prese...
2024-04-02 17:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...